As the only national payer organization that supported robust drug pricing reform, including allowing direct government negotiation for drugs without competition, we are pleased by the White House’s announcement of the first ten drugs to be negotiated.
ACHP commends Senate Finance Committee Chairman Ron Wyden (D-OR) and Ranking Member Mike Crapo (R-ID) for their leadership to reform PBMs. ACHP supports the Committee’s bipartisan efforts to increase PBM transparency, as well as modernize the industry’s revenue models.
In an op-ed for The Health Care Blog, ACHP’s President and CEO Ceci Connolly and Associate Vice President of Public Policy Michael Bagel discuss MA for Tomorrow, ACHP’s vision for the future of Medicare Advantage.
ACHP unveiled MA for Tomorrow, its vision for the future of Medicare Advantage based on five policy pillars.
ACHP is the only national payer group pushing for comprehensive drug pricing reform. Allowing Medicare to negotiate for lower prescription drug prices is an important step toward better health care for all.
ACHP is the voice of a unique approach in health care today, one that puts the patient at the center with plans and clinical teams collaborating to improve health outcomes and reduce costs. Our advocacy focuses on providing policymakers with tested solutions, rooted in a model that is proven to deliver better value for patients, employers and taxpayers.
